203 related articles for article (PubMed ID: 26627641)
1. Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab.
Koguchi Y; Hoen HM; Bambina SA; Rynning MD; Fuerstenberg RK; Curti BD; Urba WJ; Milburn C; Bahjat FR; Korman AJ; Bahjat KS
Cancer Res; 2015 Dec; 75(23):5084-92. PubMed ID: 26627641
[TBL] [Abstract][Full Text] [Related]
2. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.
Ferrucci PF; Gandini S; Battaglia A; Alfieri S; Di Giacomo AM; Giannarelli D; Cappellini GC; De Galitiis F; Marchetti P; Amato G; Lazzeri A; Pala L; Cocorocchio E; Martinoli C
Br J Cancer; 2015 Jun; 112(12):1904-10. PubMed ID: 26010413
[TBL] [Abstract][Full Text] [Related]
3. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
4. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
[TBL] [Abstract][Full Text] [Related]
5. Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma.
Krajsová I; Arenberger P; Lakomý R; Kubala E; Březinová I; Poprach A; Šťastný M; Mužík J; Melichar B
Anticancer Res; 2015 Nov; 35(11):6303-10. PubMed ID: 26504067
[TBL] [Abstract][Full Text] [Related]
6. Improved survival with ipilimumab in patients with metastatic melanoma.
Hodi FS; O'Day SJ; McDermott DF; Weber RW; Sosman JA; Haanen JB; Gonzalez R; Robert C; Schadendorf D; Hassel JC; Akerley W; van den Eertwegh AJ; Lutzky J; Lorigan P; Vaubel JM; Linette GP; Hogg D; Ottensmeier CH; Lebbé C; Peschel C; Quirt I; Clark JI; Wolchok JD; Weber JS; Tian J; Yellin MJ; Nichol GM; Hoos A; Urba WJ
N Engl J Med; 2010 Aug; 363(8):711-23. PubMed ID: 20525992
[TBL] [Abstract][Full Text] [Related]
7. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.
Felix J; Cassinat B; Porcher R; Schlageter MH; Maubec E; Pages C; Baroudjian B; Homyrda L; Boukouaci W; Tamouza R; Bagot M; Caignard A; Toubert A; Lebbé C; Moins-Teisserenc H
Int Immunopharmacol; 2016 Nov; 40():466-473. PubMed ID: 27728898
[TBL] [Abstract][Full Text] [Related]
8. High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma.
Samuels S; Ferns DM; Meijer D; van Straalen JP; Buist MR; Zijlmans HJ; Kenter GG; Jordanova ES
Tissue Antigens; 2015 Jun; 85(6):476-83. PubMed ID: 25871737
[TBL] [Abstract][Full Text] [Related]
9. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.
Wistuba-Hamprecht K; Martens A; Heubach F; Romano E; Geukes Foppen M; Yuan J; Postow M; Wong P; Mallardo D; Schilling B; Di Giacomo AM; Khammari A; Dreno B; Maio M; Schadendorf D; Ascierto PA; Wolchok JD; Blank CU; Garbe C; Pawelec G; Weide B
Eur J Cancer; 2017 Mar; 73():61-70. PubMed ID: 28167454
[TBL] [Abstract][Full Text] [Related]
10. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma.
Zaragoza J; Caille A; Beneton N; Bens G; Christiann F; Maillard H; Machet L
Br J Dermatol; 2016 Jan; 174(1):146-51. PubMed ID: 26343230
[TBL] [Abstract][Full Text] [Related]
11. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab: in previously treated patients with advanced melanoma.
Sanford M
BioDrugs; 2012 Jun; 26(3):185-93. PubMed ID: 22530681
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab.
Yuan J; Zhou J; Dong Z; Tandon S; Kuk D; Panageas KS; Wong P; Wu X; Naidoo J; Page DB; Wolchok JD; Hodi FS
Cancer Immunol Res; 2014 Feb; 2(2):127-32. PubMed ID: 24778276
[TBL] [Abstract][Full Text] [Related]
14. A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.
Weber JS; Sznol M; Sullivan RJ; Blackmon S; Boland G; Kluger HM; Halaban R; Bacchiocchi A; Ascierto PA; Capone M; Oliveira C; Meyer K; Grigorieva J; Asmellash SG; Roder J; Roder H
Cancer Immunol Res; 2018 Jan; 6(1):79-86. PubMed ID: 29208646
[TBL] [Abstract][Full Text] [Related]
15. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
[TBL] [Abstract][Full Text] [Related]
16. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.
Ferrucci PF; Ascierto PA; Pigozzo J; Del Vecchio M; Maio M; Antonini Cappellini GC; Guidoboni M; Queirolo P; Savoia P; Mandalà M; Simeone E; Valpione S; Altomonte M; Spagnolo F; Cocorocchio E; Gandini S; Giannarelli D; Martinoli C
Ann Oncol; 2016 Apr; 27(4):732-8. PubMed ID: 26802161
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
[TBL] [Abstract][Full Text] [Related]
18. Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids.
Chasset F; Pages C; Biard L; Roux J; Sidina I; Madelaine I; Basset-Seguin N; Viguier M; Madjlessi-EzrA N; Schneider P; Bagot M; Resche-Rigon M; Lebbe C
Eur J Dermatol; 2015; 25(1):36-44. PubMed ID: 25500362
[TBL] [Abstract][Full Text] [Related]
19. Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.
Wistuba-Hamprecht K; Martens A; Haehnel K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Demuth I; Steinhagen-Thiessen E; Larbi A; Schilling B; Schadendorf D; Wolchok JD; Blank CU; Pawelec G; Garbe C; Weide B
Eur J Cancer; 2016 Sep; 64():116-26. PubMed ID: 27400322
[TBL] [Abstract][Full Text] [Related]
20. Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).
Forschner A; Eichner F; Amaral T; Keim U; Garbe C; Eigentler TK
J Cancer Res Clin Oncol; 2017 Mar; 143(3):533-540. PubMed ID: 27878363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]